The US health regulatory agency’s clearance of the pharma giant Lupin Ltd.’s launch of Ganirelix Acetate injectable for women undergoing specific reproductive procedures was announced on Thursday. According to a regulatory filing by Lupin, the US Food and Drug Administration (USFDA) approved the 250 mcg/0.5 mL single-dose prefilled syringe of Ganirelix Acetate injectable, and it has since been introduced to the US market.
It is the generic equivalent of Organon USA LLC’s Ganirelix Acetate Injection, 250 mcg/0.5 mL, which is reference listed (RLD).
The injection is recommended for women undergoing controlled ovarian hyperstimulation in order to suppress early surges of luteinizing hormone (LH).
Lupin stated that Ganirelix Acetate injection’s projected yearly sales in the US were USD 87 million, citing IQVIA MAT data from December 2023.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.